Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03607890 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
A Phase 2 study of Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy and MSI-H Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 2
- Study locations
NCT03607890 is a Phase 2 study of Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy and MSI-H Tumors that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 38 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03607890, a Phase 2 study of Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy and MSI-H Tumors, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
Study Locations (2)
California
- Cedars Sinai Medical Center - Los Angeles
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-11-16 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03607890
The ClinicalTrials.gov registry entry for NCT03607890 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03607890 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03607890 about?
NCT03607890 is a clinical study titled "Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor". The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
What is the current status of trial NCT03607890?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-11-16. Estimated completion is 2026-10.
What conditions does trial NCT03607890 study?
This clinical trial studies the following conditions: Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors.
What interventions are being tested in trial NCT03607890?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT03607890?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03607890 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
All registered trials for this condition
MSI-H Tumors
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.